ArticleFrontiers in immunology2026
Interaction of CD99 and its ligands regulates immunoregulatory pathways in NK cells.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells play a key role in immune defense against tumors and viral infections through a balance of activating and inhibitory receptors. CD99 is a transmembrane glycoprotein involved in many biological processes; however, its role in NK cell receptor modulation remains incompletely understood. In this study, we investigated the effect of CD99 engagement on NK cells using a recombinant CD99 fusion protein upon stimulation with cytokine, interleukin (IL)-2. Peripheral blood mononuclear cells (PBMCs) and purified NK cells were analyzed to evaluate changes in several receptor expressions. Flow cytometric analysis demonstrated that the interaction between CD99 and its ligands modulates NK cell phenotypes, particularly through downregulation of natural cytotoxicity receptors (NCRs). Differential effects were observed between PBMCs and purified NK cell cultures, indicating the surrounding immune cell environment influences CD99-mediated immunomodulatory responses. Despite receptor modulation, no significant changes in cytokine production were observed in NK cells. These findings suggest that CD99 and its ligand interactions contribute to the regulation of NK cell activation states and receptor dynamics under activated conditions in a context-dependent manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.